Literature DB >> 12946495

[Vasodilatory septic shock refractory to catecholamines: is there a role for terlipressin?].

J L Fellahi1, P Bénard, G Daccache, E Mourgeon, J L Gérard.   

Abstract

We report two patients in vasodilatory septic shock refractory to catecholamines in which a continuous infusion of terlipressin was associated with a dramatic increase in systemic arterial blood pressure and short-term survival. Low doses of terlipressin were sufficient in both cases (0.01-0.0 mg h(-1)) to restore blood pressure by increase of systemic vascular resistances. The haemodynamic response was immediate, long-acting, dose-dependent and reversible in a few hours when the drug administration was stopped. A further increase in terlipressin dose regimen markedly decreased cardiac performance. Terlipressin simultaneously induced vasoconstriction within the cutaneous vascular territory, leading to local skin necrosis. The splanchnic vascular territory seemed to be constricted in the same way. Further studies are needed to better understand and precise the role of terlipressin in the treatment of vasodilatory septic shock refractory to catecholamines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12946495     DOI: 10.1016/s0750-7658(03)00218-1

Source DB:  PubMed          Journal:  Ann Fr Anesth Reanim        ISSN: 0750-7658


  4 in total

1.  Continuous terlipressin infusion in patients with septic shock: less may be best, and the earlier the better?

Authors:  Andrea Morelli; Christian Ertmer; Matthias Lange; Martin Westphal
Journal:  Intensive Care Med       Date:  2007-05-25       Impact factor: 17.440

Review 2.  Vasopressin vs. terlipressin in the treatment of cardiovascular failure in sepsis.

Authors:  Matthias Lange; Christian Ertmer; Martin Westphal
Journal:  Intensive Care Med       Date:  2007-12-08       Impact factor: 17.440

3.  Rescue treatment with terlipressin in children with refractory septic shock: a clinical study.

Authors:  Antonio Rodríguez-Núñez; Jesús López-Herce; Javier Gil-Antón; Arturo Hernández; Corsino Rey
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

Review 4.  Rescue therapy in septic shock--is terlipressin the last frontier?

Authors:  Marc Leone; Claude Martin
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.